ADVA
11.5.2022 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Westfalen Weser Netz has deployed its ALM fiber monitoring technology for precise, real-time insight into its regional metro network. The solution gives the municipal utility provider complete infrastructure assurance. Now it can instantly detect and rapidly repair fiber breaks with minimal disruption. The ADVA ALM enables Westfalen Weser Netz to dramatically shorten repair cycles and enhance network performance. It also means far fewer truck rolls and significant savings on fuel cost. The technology integrated seamlessly into Westfalen Weser Netz’s cableScout® management software provided by ADVA’s partner JO Software Engineering GmbH.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510005843/en/
“The ADVA ALM is helping us ensure excellent network availability while also reducing maintenance effort and expense. It gives our repair teams the power to remotely measure attenuation and quickly locate any degradation in our fiber plant. They can then take action straightaway to resolve problems,” said Stefan Kenneweg, consultant at Westfalen Weser Netz. “Combining the ADVA ALM assurance solution with our cableScout® management software is like turning on the lights right across our network. Now there are no more blind spots. That means no more wasted hours on false alarms and no nasty surprises for our customers.”
The ADVA ALM is now delivering passive, in-service monitoring of Westfalen Weser Netz’s fiber links. The simple, plug-and-play device offers several key advantages for utility network assurance. Its fanless operation and compact, low-energy design reduce opex and environmental impact. It’s also a highly robust solution ready to be installed in almost any location. Built on standardized, open management interfaces, the ADVA ALM is fully interoperable with Westfalen Weser Netz’s existing cableScout® software. This provides a geographic information system (GIS) to quickly and easily locate failures.
“Our ALM fiber monitoring platform is already bringing major benefits to Westfalen Weser Netz and its customers, helping the company reduce truck rolls and maximize resource efficiency. There really is no technology that has this much impact with such little cost and effort,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “When it comes to providing homes and businesses with safe, efficient and sustainable electricity, gas and water, the reliability of the data transport network is crucial. Now that Westfalen Weser Netz has total visibility and control of its fiber infrastructure, it can avoid outages and introduce new services with confidence.”
“Our cableScout® platform combined with the ADVA ALM solution for in-service monitoring provides Westfalen Weser Netz with continual access to a detailed layout of its network. Its team now has comprehensive understanding of the complete fiber architecture, enabling efficient end-to-end planning, management and troubleshooting,” said Ralph Kosztovits, managing partner at JO Software Engineering GmbH. “ADVA is a company that shares our commitment to sustainable growth and creating new opportunities through innovation. Our close alliance offers major benefits for network operators like Westfalen Weser Netz who are committed to empowering customers to achieve more and enhancing end user experience.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005843/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom